46 Life Technologies
™
| Genome editing
Superior Transfection Reagents
Improve gene editing outcomes
Lipofectamine
®
3000 reagent was developed to break through the boundaries
of traditional delivery methods and facilitate new technologies, such as genome
engineering, in more biologically-relevant systems. With this reagent, GeneArt
®
CRISPR vectors targeting the AAVS1 locus in HepG2 and U2OS cells show improved
transfection efficiency (Figure 11), mean fluorescence intensity, and genomic
cleavage. High transfection and genome editing efficiency is also observed
with GeneArt
®
Precision TALs. These advancements in delivery help minimize
painstaking downstream workflows, enable easier stem cell manipulation, and
enhance site-specific insertion of transgenes into the genome.
Mean
OFP
intensity
0
50,000
100,000
150,000
3 L Lipofectamine
®
2000 1.5 L Lipofectamine
®
3000
B
Mean
OFP
intensity
0
50,000
100,000
150,000
200,000
3 L Lipofectamine
®
2000 1.5 L Lipofectamine
®
3000
A
Figure 11. Transfection efficiency and protein expression using GeneArt
®
CRISPR Nuclease Vector. The vector
contained an orange fluorescent protein (OFP) reporter gene and was transfected with Lipofectamine
®
2000 or
Lipofectamine
®
3000 reagent into (A) U2OS and (B) HepG2 cell lines. Bar graphs show reporter gene expression;
images show fluorescence of corresponding cells expressing OFP.
